Empagliflozin in posttransplantation diabetes mellitus: A prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety

American Journal of Transplantation

Volumn 19, Issue 3, 2019, Pages 907-919

  Schwaiger, Elisabeth ^a   Burghart, Lukas ^a   Signorini, Lorenzo ^b   Ristl, Robin ^a   Kopecky, Chantal ^a   Tura, Andrea ^c   Pacini, Giovanni ^c   Wrba, Thomas ^a   Antlanger, Marlies ^a   Schmaldienst, Sabine ^d   Werzowa, Johannes ^e   Säemann, Marcus D ^a,f   Hecking, Manfred ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c CNR   (Italy)

^d KAISER FRANZ JOSEF HOSPITAL   (Austria)

^e HANUSCH HOSPITAL   (Austria)

^f WILHELMINEN HOSPITAL   (Austria)

Author keywords

clinical research practice; diabetes: new onset posttransplant; endocrinology diabetology; kidney (allograft) function dysfunction; kidney transplantation nephrology; metabolism metabolite

Indexed keywords

ANTIBIOTIC AGENT; EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; METFORMIN; SITAGLIPTIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; BALANITIS; BLOOD GLUCOSE MONITORING; BODY COMPOSITION; BODY FLUID; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE DURATION; ESTIMATED GLOMERULAR FILTRATION RATE; FEMALE; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; HYPONATREMIA; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN SENSITIVITY; INSULIN TREATMENT; KIDNEY GRAFT; MALE; MIDDLE AGED; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; ORTHOSTATIC INTOLERANCE; PATIENT SAFETY; PRIORITY JOURNAL; TOTAL BODY WATER; URINARY TRACT INFECTION; ADVERSE EVENT; EARLY INTERVENTION; FOLLOW UP; GLUCOSE BLOOD LEVEL; GRAFT REJECTION; GRAFT SURVIVAL; METABOLISM; PANCREAS ISLET TRANSPLANTATION; PILOT STUDY; POSTOPERATIVE COMPLICATION; PROGNOSIS; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK FACTOR;

BENZHYDRYL COMPOUNDS; BLOOD GLUCOSE; BODY COMPOSITION; BODY FLUIDS; DIABETES MELLITUS, TYPE 2; EARLY MEDICAL INTERVENTION; FEMALE; FOLLOW-UP STUDIES; GLUCOSIDES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; INSULIN; ISLETS OF LANGERHANS TRANSPLANTATION; MALE; MIDDLE AGED; PATIENT SAFETY; PILOT PROJECTS; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RISK FACTORS; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85060609343     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/ajt.15223     Document Type: Article

References (30)

1. Sharif A, Baboolal K. Complications associated with new-onset diabetes after kidney transplantation. Nat Rev Nephrol. 2011;8(1):34-42.
2. Hecking M, Werzowa J, Haidinger M, et al. Novel views on new-onset diabetes after transplantation: development, prevention and treatment. Nephrol Dial Transplant. 2013;28(3):550-566.
3. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international consensus meeting on posttransplantation diabetes mellitus: recommendations and future directions. Am J Transplant. 2014;14(9):1992-2000.
4. Hecking M, Haidinger M, Doller D, et al. Early basal insulin therapy decreases new-onset diabetes after renal transplantation. J Am Soc Nephrol. 2012;23(4):739-749.
5. Chakkera HA, Weil EJ, Pham PT, Pomeroy J, Knowler WC. Can new-onset diabetes after kidney transplant be prevented? Diabetes Care. 2013;36(5):1406-1412.
6. Werzowa J, Saemann M, Haidinger M, Krebs M, Hecking M. Antidiabetic therapy in post kidney transplantation diabetes mellitus. Transplant Rev (Orlando). 2015;29:145-153.
7. Akhtar N. Type 2 diabetes mellitus and Invokana: an FDA approved drug. Curr Diabetes Rev. 2013;9(6):478-490.
8. Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int. 2009;75(12):1272-1277.
9. Chao EC, Henry RR. SGLT2 inhibition–a novel strategy for diabetes treatment. Nat Rev Drug Discov. 2010;9(7):551-559.
10. Liakos A, Karagiannis T, Athanasiadou E, et al. Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab. 2014;16(10):984-993.
11. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117-2128.
12. Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644-657.
13. Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323-334.
14. Heerspink HJ, Desai M, Jardine M, Balis D, Meininger G, Perkovic V. Canagliflozin slows progression of renal function decline independently of glycemic effects. J Am Soc Nephrol. 2017;28(1):368-375.
15. Sattar N, McLaren J, Kristensen SL, Preiss D, McMurray JJ. SGLT2 Inhibition and cardiovascular events: why did EMPA-REG outcomes surprise and what were the likely mechanisms? Diabetologia. 2016;59(7):1333-1339.
16. Rajasekeran H, Lytvyn Y, Cherney DZ. Sodium-glucose cotransporter 2 inhibition and cardiovascular risk reduction in patients with type 2 diabetes: the emerging role of natriuresis. Kidney Int. 2016;89(3):524-526.
17. Inzucchi SE, Zinman B, Fitchett D, et al. How does empagliflozin reduce cardiovascular mortality? Insights from a mediation analysis of the EMPA-REG Outcome trial. Diabetes Care. 2018;41(2):356-363.
18. Sharif A, Cohney S. Post-transplantation diabetes-state of the art. Lancet Diabetes Endocrinol. 2016;4(4):337-349.
19. Roden M, Weng J, Eilbracht J, et al. Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2013;1(3):208-219.
20. Roden M, Merker L, Christiansen AV, et al. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naive patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154.
21. Lebovitz HE. Insulin: potential negative consequences of early routine use in patients with type 2 diabetes. Diabetes Care. 2011;34(Suppl 2):S225-S230.
22. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130(6):461-470.
23. Ernstbrunner M, Kabon B, Zotti O, et al. Intravenous fluid challenge decreases intracellular volume: a bioimpedance spectroscopy-based crossover study in healthy volunteers. Sci Rep. 2017;7(1):9644.
24. Rosenstock J, Ferrannini E. Euglycemic diabetic ketoacidosis: a predictable, detectable, and preventable safety concern with SGLT2 inhibitors. Diabetes Care. 2015;38(9):1638-1642.
25. Hecking M, Kainz A, Werzowa J, et al. Glucose metabolism after renal transplantation. Diabetes Care. 2013;36(9):2763-2771.
26. Al Jobori H, Daniele G, Adams J, et al. Empagliflozin treatment is associated with improved beta cell function in T2DM. J Clin Endocrinol Metab. 2018;103:1402-1407.
27. U.S. Food and Drug Administration. https://www.fda.gov/Drugs/DrugSafety/ucm475463.htm. Accessed April 28, 2018.
28. Liu J, Li L, Li S, et al. Effects of SGLT2 inhibitors on UTIs and genital infections in type 2 diabetes mellitus: a systematic review and meta-analysis. Sci Rep. 2017;7(1):2824.
29. Saemann M, Horl WH. Urinary tract infection in renal transplant recipients. Eur J Clin Invest. 2008;38(suppl 2):58-65.
30. Abbott KC, Swanson SJ, Richter ER, et al. Late urinary tract infection after renal transplantation in the United States. Am J Kidney Dis. 2004;44(2):353-362.